Nasdaq
$0.7331▲ 1.30%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $65.6MShares out 89.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 3d agoPre-market26.10.22 19:068-KKey event#●●●#●●●#●●●
COGNITION THERAPEUTICS INCBullish
Cognition Therapeutics has reached an alignment with the U.S. FDA on key elements of the Phase 3 clinical trial design for its lead candidate, zervimesine (CT1812), in dementia with Lewy bodies (DLB). The agreement covers patient selection, dosage, duration, and endpoints, allowing the company to finalize the protocol for the planned registrational study.…more
$0.7331+1.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.7Pre-market26.08.07 20:3010-QEarnings
COGNITION THERAPEUTICS INC
코그니션 테라퓨틱스(CGTX)는 2026년 6월 30일 기준 분기 보고서(10-Q)를 통해 2026년 8월 4일 기준 총 95,093,746주의 보통주가 발행 및 유통되고 있음을 공시했습니다. 또한, 회사는 2026년 4월 6일 체결된 임대차 계약 수정안을 통해 본사 사무실을 기존 2,864평방피트에서 4,200평방피트로 확장하고, 임대 기간을 2031년 3월 31일까지 연장했습니다.…more
$0.7331+1.30%vs prev closeView filingShare - 8.6After-hours26.08.07 05:188-KKey event
COGNITION THERAPEUTICS INC
코그니션 테라퓨틱스는 2026년 2분기 매출액 없이 393만 달러의 순손실과 주당순손실 0.04달러를 기록했습니다. 회사는 2026년 6월 30일 기준 3,480만 달러의 현금을 보유하여 2027년 4분기까지 운영 자금을 확보했으며, 루이소체 치매(DLB) 치료제 '제르비메신'의 임상 3상을 2027년 중반에 개시할 계획입니다.…more
$0.7331+1.30%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 19:00#●●●#●●●
Cognition Therapeutics Aligns with FDA on Phase 3 Trial Design for Zervimesine…more
Cognition Therapeutics has reached an agreement with the FDA on the key design elements for its Phase 3 registrational study of Zervimesine in patients with dementia with Lewy bodies. While this alignment reduces regulatory uncertainty, the company must still successfully complete the trial to demonstrate clinical efficacy.…more
$0.7331+1.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.13Pre-market26.10.13 19:00
●●●●●●●● ●●●●● ●●●●●●
Cognition Therapeutics has been granted a new patent for a crystalline form of its lead drug candidate, zervimesine, extending its intellectual property protection until 2045. This development provides a more stable pharmaceutical profile suitable for large-scale manufacturing ahead of planned Phase 3 trials.…more
$0.7331+1.30%vs prev close - 9.29Pre-market26.09.29 20:30
●●●●●●●● ●●●●● ●●●●●●
Cognition Therapeutics has scheduled a Type C meeting with the FDA on October 20 to align on primary endpoints for the upcoming Phase 3 trial of zervimesine. This meeting is a critical step in finalizing the study design for treating psychosis in patients with dementia with Lewy bodies.…more
$0.7331+1.30%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report